MRRPhysical AI
intelligence
← Company intelligence

Robot maker · registered

Cellares

Corporate marketmedicalmanufacturingCurated record
cellares.com

Cellares builds the Cell Shuttle, an automated end-to-end robotic platform for manufacturing cell and gene therapies at industrial scale. The platform handles the full manufacturing lifecycle — from cell activation and engineering to formulation and fill/finish — in a closed, automated environment. In April 2025, the Cell Shuttle received FDA Advanced Manufacturing Technology designation. Cellares operates as a contract development and manufacturing organization (CDMO), supplying manufacturing capacity rather than developing therapies itself.

HeadquartersSouth San Francisco, US
FoundedNot listed
Corporate funding$644M
Team201-500
Deployments9
Open roles0
01

Company overview

Identity and operating footprint

Company typeRobot maker
Market segmentCorporate
StageSeries D
FoundersFabian Gerlinghaus (Co-Founder & CEO), Omar Kurdi (Co-Founder & President), Alex Pesch (Co-Founder & CTO)
Regions servedNorth America, Europe, Asia
Countries deployedNot listed
Service footprintNot listed
Last reviewed2026-07-05
MX

Robot models

Specifications remain vendor-claimed

Machineamr

Cell Q

  • No specifications on file.
Machinemedical

Cell Shuttle

  • End-to-end automated cell therapy manufacturing platform with FDA Advanced Manufacturing Technology designation

    Closed robotic platform for industrial-scale CAR-T and gene therapy production

    Claim source
DP

Deployment log

Announced and cited only

AnnouncedCustomerSiteCountryCountEvidence
2026-07-13Sonoma Biotherapeuticspharma_clinical_manufacturingUSNot disclosedAnnouncement
2026-06-03TScan Therapeuticspharma_clinical_manufacturingUSNot disclosedAnnouncement
2026-05-11ProTgenpharma_clinical_manufacturingUSNot disclosedAnnouncement
2026-04-14Cabaletta Biopharma_clinical_manufacturingUSNot disclosedAnnouncement
2026-02-18University of Wisconsin — Madisonacademic_medical_centerUSNot disclosedAnnouncement
2026-01-08City of Hopecancer_research_centerUSNot disclosedAnnouncement
2026-01-06Autolus Therapeuticspharma_clinical_manufacturingGBNot disclosedAnnouncement
2024-06-27Kite (Gilead Sciences)pharma_manufacturingUSNot disclosedAnnouncement
2024-04-22Bristol Myers Squibbpharma_manufacturingUSNot disclosedAnnouncement
CA

Funding history

Publicly announced rounds

Investors on recordBlackRockEclipseARK Invest
TL

Company timeline

Milestones and announcements

2026-01-01Raised $257M Series D led by BlackRock and Eclipse to fund global factory buildout across US, Netherlands, and JapanDrug Discovery Trends
2025-04-01FDA granted Advanced Manufacturing Technology designation to the Cell Shuttle platformDrug Discovery Trends
SC

Source ledger

7 unique public sources

01
Cellares Grows Series D to $327 Million with $50 Million Prime Radiant Partners InvestmentYahoo Finance / Cellares · retrieved 2026-07-05
02
Cellares raises $257M Series D to automate cell therapy manufacturingDrug Discovery Trends · retrieved 2026-07-05
03
Cellares Raises $255M Series C to Launch First Integrated Development and Manufacturing Organization (IDMO)Cellares · retrieved 2026-07-05
04
Cellares News Archive — Series BCellares · retrieved 2026-07-05
05
Cellares and UW-Madison partner to automate CAR-T manufacturingDrug Discovery Trends · retrieved 2026-07-05
06
Cellares Announces Agreement with Kite to Evaluate Its Cell Shuttle Automated Manufacturing PlatformCellares · retrieved 2026-07-05
07
Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply AgreementCellares · retrieved 2026-07-05